Published: Send to a friend XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week WASHINGTON andMENLO PARK, Calif., Oct. 10 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that it plans to present long-term follow-up data from the CUSTOM I, II and III clinical trials next week at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) meeting inWashington, DC. The CUSTOM clinical trials are prospective studies designed to investigate the safety and efficacy of the Custom NX(R) drug eluting stent (DES) system in treating patients with coronary artery disease. Pieter R. Stella, MD, Director, Cardiovascular Research, University Medical CentreUtrecht, The Netherlands, and one of the CUSTOM clinical trial investigators, will present the data during a scientific symposium entitled, "The Drug Eluting Stent Summit, Part II," on Monday, October 13, 2008 at 2:54 p.m., eastern time, at the Walter E. Washington Convention Center, Ballroom C, Level 3. The data presentation will be posted on the XTENT website at http://www.xtentinc.com. About XTENT XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death inthe United States andEurope. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning the timing of the release of its clinical trial data. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's quarterly report on Form 10-Q for the quarter ended June 30, 2008. This quarterly report was filed with the SEC on August 12, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. SOURCE XTENT, Inc. Copyright © 2008, PRNewswire Copyright © 2008, NewsBlaze, Daily News Tags: ,HEA,MTC,BIO,TRI,TDS,DC-XTNT-TRI-Data-to    _   _             Is your favorite bookmark site missing? Ask for it.